Ropes & Gray represented TRexBio, an Eli Lilly-backed clinical-stage biotechnology company, in its $116.7 million initial public offering of 8,333,334 shares of its common stock at a price per share of $14. The offering priced on October 8 and closed on October 13. TRexBio's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "TRXB".
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
The team was led by capital markets partner Tara Fisher and included emerging companies and venture capital partner Raj Banerjee, executive compensation & benefits partner Renata Ferrari, life sciences regulatory & compliance partner Josh Oyster, and health care partner Eve Brunts.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.